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ABSTRACT 
Objective: The present investigation was to design pellets loaded with Indomethacin for extended release. Indomethacin is a non steroidal anti 
inflammatory drug (NSAID) commonly used for reduction of pain and inflammation. To improve the bioavailability indomethacin was prepared by 
fluidised bed coating tablet technology.  
Methods: Indomethacin pellets were prepared using hydroxy propyl methyl cellulose and ethyl cellulose as a polymer in different concentration. 
Pellets were evaluated for physico - chemical properties such as hardness, friability, thickness, weight variation, drug content uniformity and 
capsule lock length. In vitro drug release studies were carried out USP rotating basket type I method and the samples were analyzed at 319nm by UV 
spectrophotometer. 
Results: FT-IR studies revealed that there was no interaction betweeen drug and polymers used in the study. The drug release from F5 formulation 
was found to zero order kinetic model. It was also found linear in higuchi plot which confirms that diffusion is one of the mechanism of drug release. 
Conclusion: Among these formulations, Formulation (F5) containing Ethyl cellulose (4cps) 5mg & HPC 20 mg and extended release coating upto 
7% showed optimized release pattern.The optimized formulation (F5) releases the drug upto 24hrs and fulfilled the requirements such as cost 
effective and high patient compliance. 
Keywords: Indomethacin, Pellet technology, Zero order kinetic model. 
 
INTRODUCTION 
Indomethacin is a non-steroidal anti–inflammatory drug used in the 
symptomatic management of painful and inflammatory conditions 
such as rheumatoid arthritis and osteoarthritis. The most frequent 
adverse effects are gastro– intestinal (GI) and central nervous 
system disturbances [1].The traditional dosage forms of 
indomethacin such as tablets and capsules have to be taken three or 
four times per day. Most patients on this therapeutic regimen are 
elderly, often taking several other tablets or capsules per day for the 
treatment of other disease states, such as hypertension and 
depression. Accordingly, it is important to keep the number of unit 
doses per day at minimum in order to ensure patient’s compliance to 
the particular therapeutic regimen. In addition, it is important, 
particularly in the treatment of rheumatoid arthritis, to maintain a 
constant antiinflammatory serum concentration of indomethacin. It 
is difficult to reach this goal by modifying the traditional dosage 
forms of indomethacin, as they are rapidly absorbed and provide 
high serum concentrations. Then, they are slowly metabolized and 
their serum concentrations fall down [2].These led to investigation 
of new dosage forms such as delayed release, extended release or 
enteric release formulations to minimize these symptoms. Intestinal 
complaints due to the conventional formulations of indomethacin 
capsules are rare [3] as they release the total content in the powder 
form, which disperses in the gastric fluid, avoiding any possibility of 
causing localized release as seen in the monolithic devices. Previous 
observations recommend continuous release indomethacin as an 
agent with relatively low rates of acute gastric mucosal bleeding.The 
advantage of controlled release capsules, it would be ideal to 
formulate this product as a multi-particulate system filled in 
capsules. There are various techniques for preparation of sustained 
release indomethacin, like microencapsulation, coating by use of 
Wurster column process, and preparing pellets by an extrusion 
/spheronization process [5].Wurster column process is one of the 
methods reported for production of indomethacin pellets [4-6]. 
Currently much emphasis has laid on multi-particulate dosage forms 
because of their multiple advantages over single unit dosage forms, 
like flexibility during formulation development and therapeutic 
benefits for the patients. These include increased bioavailability, 
predictable gastric emptying, and reduced risk of local irritation and 
systematic toxicity due to dose dumping [7,8]. The most attractive 
features of the powder layering system are the uniform distribution 
of the powder on cores and the high drying efficiency of the binder 
solution, as well as the easy-to-clean pan and possibility of applying 
the successive functional film coating using the same equipment. 
The critical aspects involved in the process of layering activated-
surface powder using the aqueous binder solution are decreased 
adhesiveness of the binder on cores due to the presence of a wetting 
agent and the high latent heat of vaporization of water used as a 
binder vehicle [9-11].The objective of this study was to develop an 
extended release pellet formulation of indomethacin by the 
centrifugation (rotary fluid bed granulation) or powder layering 
method for the first time, which provides a prolonged anti-
inflammatory effect by ingestion of only one unit dose every 12 
hours. This method was chosen because of the difficulty in managing 
the indomethacin powder with 1-3 mg in size and attractive features 
of the powder layering system. Further coating trials were 
undertaken to achieve a final formulation, meeting all the USP30 
requirements. As recommended dosage for indomethacin extended 
release formulation is 75-150 mg daily [12], it was best suited to 
develop a 75 mg. 
MATERIALS AND METHODS 
Indomethacin was obtained from fabbrica Italiana sintetici, Itali. 
Hydroxy propyl cellulose was obtained from Hercules, china. Ethyl 
cellulose, Isopropyl alcohol, sodium lauryl sulphate, povidone k-30 
were purchased from Merck, Mumbai. Talc and Sugar Spheres (500-
600mm) was purchased from CDH (p) Ltd, New Delhi, India. All the 
chemicals used were of A.R. grade. 
Methodology 
Construction of standard curve for Indomethacin. 
Indomethacin (100mg) was dissolved in 100ml of methanol from 
this solution 5ml was withdrawn and diluted to 100ml with 
phosphate buffer PH 6.2. Indomethacin is estimated 
spectrophotometrically at 319nm and it obeys beer-lamberts law in 
the range of 50mg/ml. 
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Preformulation studies 
Performulation study is an investigation of physical and chemical 
properties of drug substance alone and in combination with excipients 
Drug – Excepient compatibility studies 
Pure drug and excepients in 1:1 ratio in glass vials were kept at 
various accelerated conditions in stability chamber. If there is no 
colour changes were selected for formulation development 
FTIR study [Fourior transformer IR study] 
Identification of pure and polymers were performed using Infrared 
Spectroscopy by KBR pellet method. 
Particle size distribution of Indometnacin powder 
It is estimated by using a Mastersizer-2000 particle size analyzer. 
Indomethacin powder was taken into the analyzing chamber 
containing deionized water as the medium. A few drops of triton 
solution was added to disperse the powders and the powder was 
examined under microscope with a magnification of 400x. 
Formulation of Extended release pellets 
Extended release pellets were prepared by Fluid bed processor. 
Preparation of drug layering solution 
Isopropyl alcohol was taken in a suitable vessel and added ethyl 
cellulose 4cps. Sodium lauryl sulphate, Hydroxy propyl cellulose and 
water were added to the above solution until it dissolves completely. 
Then Indomethacin was added slowly to form a uniform dispersion. 
Then it was passed through sieve 740 sugar spheres were loaded 
into wurster column and the dispersion was sprayed onto sugar 
spheres.  
The drug layered pellets was dried with low fluidization at a bed 
temperature of 40 to 5c. The pellets were stored in suitable 
container. 
Extended release coating 
Extended release coating solution in which polymer concentration 
1:1 ratio was prepared (5%, 7%, and 9%). Isopropyl alcohol mixed 
with ethyl cellulose 4cps, purified water, and Hydroxy propyl 
cellulose. This solution is used for extended release purpose.  
The drug layered pellets were loaded into wurster columns the 
solution was sprayed onto drug layered pellets. The extended 
release coated pellets was dried at a bed temperature of 40 ±5°c. 
The talc was passed through #40 sieze and pellets were lubricated. 
 
Table 1: Formulation chart of Indomethacin pellet 
Ingredients  Quantity per unit (mg) 
 F1 F2 F3 F4 F5 F6 
Indomethacin 75 75 75 75 75 75 
Ethyl cellulose (4cps)  5 5 5 7 5 5 
Povidone k30 20 - - - - - 
Hydroxypropyl Cellulose, Low-substituted - 20 - - - - 
Hydroxypropyl Cellulose - - 20 18 20 20 
Sodium lauryl sulfate 0.5 0.5 0.5 0.5 0.5 0.5 
Talc 1 1 1 1 1 1 
Sugar spheres (500-600µm) 217.5 217.5 217.5 217.5 217.5 217.5 
Isopropyl alcohol q.s  q.s  q.s  q.s  q.s  q.s  
Purified water q.s  q.s  q.s  q.s  q.s  q.s  
 
Table 2: Extended release coating 
Ingredients Quantity per unit (mg) 
 F1 F2 F3 F4 F5 F6 
Ethyl cellulose (4cps) 8 8 8 8 11 14 
Povidone k30 8 - - - - - 
Hydroxypropyl Cellulose, Low-substituted - 8 - - - - 
Hydroxypropyl Cellulose   8 8 11 14 
Sodium lauryl sulfate 1 1 1 1 1 1 
Isopropyl alcohol qs qs qs qs qs qs 
Purified water qs qs qs qs qs qs 
Extended release pellet weight 336 336 336 336 342 348  
Talc 1 1 1 1 1 1 
 
Evaluation of Pellets 
The Properties of pellets such as weight variation, content 
uniformity and loss on drying were determined. Weight variation 
was performed according to IP procedure. 
 
The drug content was determined by weighing 10 capsules 
individually and one capsule was transferred into 100ml equal 
volume of methanol and phosphate buffer PH 6.2 The solution was 
filtered and after suitable dilution its absorbance was measured at 
319nm by UV visible Spectrophotometer [Shimadzu 1700] 
Loss on drying was measured by using Electronic Loss on drying 
apparatus. Bulk density, Tapped density, Carr’s index and Hausner’s 
ratio were performed for Indomethacin pellets. 
Invitro drug release studies 
Invitro drug release of Indomethacin Extended release pellets was 
performed using USP Basket type apparatus [Electrolab TDT 08L-8 
Basket dissolution apparatus] with a stirring speed 75 rpm at 37 
t0.5c in 900ml of 6.2 phosphate buffer for 24 hours. Then 5ml 
samples were collected at 1 hour, 2 hour, 4hour, 6hour, 12 hour and 
24 hours from midway between the surface of dissolution medium 
and the top of the rotating basket, not less than 1cm from the vessel 
wall and replace fresh buffer solution. After appropriate dilution and 
the Samples were analyzed at 319nm by UV Spectrophotometer. 
Kinetic Modeling 
The invitro release data was analyzed by the zero order kinetics 
equation as well as Higuchi’s and Korsmeyer – Peppa’s equation to 
understand the release profile and release mechanism. When a 
graph of the cumulative percentage of the drug released from the 
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pellet against time is plotted zero order release is linear in such a plot, 
indicating that the release rate is independent of concentration. The rate 
of release of the drug can be described mathematically as follows, 
Rate of release = dcs/dt= k 
CS= Concentration of the drug present in the matrix 
t = time 
k = rate constant 
Hence to confirm the exact mechanism of drug release from the 
extended release pellets the data was computed and graphed 
according to Higuch’s equation and korsemeyer peppa’s equation  
RESULTS AND DISCUSSION 
The Compatibility between the drug and polymer was found to be 
good by these studies. From this study, it was observed that 
mixtures shown have no colour change.  
FTIR Spectrum of Indomethacin & optimized formulation of 
Indomethacin extended release pellets were compared, there were 
no major changes in position of the spectrum it indicates the 
absence of physical and chemical interaction of Indomethacin 
extended release pellets.  
The Bulk density, Tap density carr’s Index and Hausner’s ratio of 
Indomethacin extended release pellets were shown below the Table.
 
Table 3: Physico- chemical characteristics of indomethacin extended release pellets 
Formulation code Bulk density Tap density(g/cc) Carr’s Index (g/cc) Hausner’s ratio  
F-1 0.837±0.007 0.890±0.007 6.01±1.57 1.074±0.017 
F-2 0.833±0.012 0.886±0.015 6.012±0.79 1.06±0.008 
F-3 0.821±0.011 0.873±0.019 5.978±0.82 1.06±0.009 
F-4 0.837±0.013 0.886±0.015 5.698±0.25 1.058±0.005  
 F-5 0.845±0.012 0.899±0.008 6.209±0.63 1.049±0.030 
 F-6 0.873±0.014 0.918±0.008 4.866±0.73 1.036±0.017 
All these values are lies with in the range which shows good flow property. The content uniformity of Indomethacin extended release pellets were 
within the limits (90% to 110%). This shows that the drug was uniformly distributed Content uniformity and Capsule lock length were shown 
below the table. 
 
Table 4: Content uniformity and Capsule lock length of Indomethacin extended release pellets 
Formulation code Content Uniformity Capsule lock length in  (mm) 
F-1 99.1±0.73 19.30±0.10 
F-2 99.4±0.95 19.33±0.09 
F-3 100.9±0.66 19.35±0.10 
F-4 98.3±1.05 19.31±0.09 
F-5 100.7±1.19 19.33±0.11 
F-6 99.5±0.92 19.23±0.12 
Weight variation and loss on drying for prepared Extended release pellets were within the IP limit. Weight variation of all the extended release 
pellets was within the ± 7.5 Moisture content of the pellets were around 1%. 
 
Table 5: Weight variation and loss on drying of Indomethacin extended release pellets 
Formulation code Weight (mg) ±SD Loss on drying (%) 
F-1 409±1.89 1.22±0.02  
F-2 409±2.63 1.20±0.03 
F-3 409±2.78 1.17±0.02  
F-4 409±2.52 1.18±0.02  
F-5 415±2.02 1.21±0.02  
 F-6 410±1.89 1.20±0.03  
The invitro drug release profile of Indomethacin extended release pellets (F5) was shown in figure. The results indicated extended release of drug 
from all the formulations with increase in polymer concentration formulation (F5) composed of Ethyl cellulose (4cps) 5mg & HPC 20 mg and 
extended release coating upto 7% showed optimized release pattern. 
 
 
Fig. 1: Release profile of Indomethacin extended release pellets 
F-5 formulation 
 
Fig. 2: Zero order kinetic model of F-5 formulation 
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Fig. 3: Higuchi plot of F-5formulation. 
 
CONCLUSION 
The present research was carried out to develop a Indomethacin 
extended release pellets using ethyl cellulose and hydroxy propyl 
cellulose as a polymer. Formulation (F5) containing Ethyl cellulose 
(4cps) 5mg & HPC 20 mg and extended release coating upto 7% 
showed optimized release pattern. Pellets technique using ethyl 
cellulose as a retardant has successfully extended the release of 
indomethacin from its pellet formulation. The pellet formulation 
also reduced dosing frequency, increased bioavailability and provide 
better patient compliance. 
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